BridgeBio Oncology Therapeutics (BBOT) has successfully completed its business combination with Helix Acquisition Corp. II, raising approximately $382 million in gross proceeds to advance its pipeline of next-generation RAS-targeted cancer therapeutics. The transaction closed on August 11, 2025, following shareholder approval on August 4, 2025, with BBOT shares beginning trading on the Nasdaq Global Market under ticker symbol "BBOT" on August 12, 2025.
The financing structure combined approximately $120 million from the former Helix trust account with a $261 million private investment in public equity (PIPE) led by Cormorant Asset Management. Notably, the transaction achieved a redemption rate of only 39%, marking the second lowest redemption rate for a biotech de-SPAC transaction since 2022, demonstrating strong investor confidence in BBOT's therapeutic approach.
Targeting Critical Cancer Pathways
BBOT is advancing a clinical-stage pipeline focused on RAS and PI3Kα malignancies, targeting what the company describes as "the two most prevalent oncogenes in human tumors." The company's approach aims to improve outcomes for patients with cancers driven by these critical pathways through novel small molecule therapeutics.
"The successful completion of our business combination, with a relatively low redemption rate of approximately 39%, is a pivotal milestone that underscores the strong conviction of our investors in our vision," said Eli Wallace, PhD, Chief Executive Officer of BBOT. "With meaningful progress across all three of our pipeline programs, we are entering this next chapter as a public company with significant momentum."
Three-Program Clinical Pipeline
The company's pipeline includes three distinct clinical-stage programs, each targeting different aspects of RAS pathway malignancies:
BBO-8520 represents a direct inhibitor of KRASG12C in both the ON and OFF states, currently being evaluated in the Phase 1 ONKORAS-101 trial (NCT06343402) for patients with KRASG12C mutant non-small cell lung cancer. The compound is being tested both as monotherapy and in combination with pembrolizumab, with its ability to directly inhibit the ON state and block effector binding differentiating it from other KRASG12C targeting approaches.
BBO-10203 offers a novel mechanism as an orally bioavailable small molecule that selectively blocks the physical interaction between RAS and PI3Kα, resulting in inhibition of RAS-driven PI3Kα-AKT signaling without the risk of hyperglycemia. This mechanism makes BBO-10203 agnostic to the mutational status of either RAS or PI3Kα, providing potential to treat tumors driven by KRAS or PI3Kα mutations. The compound is being evaluated in the Phase 1 BREAKER-101 trial (NCT06625775) for patients with HER2+ amplified or HR+/HER2- breast cancer, and KRAS mutant colorectal or non-small cell lung cancer.
BBO-11818 functions as a panKRAS inhibitor targeting mutant KRAS in both ON and OFF states with strong potency against KRASG12D and KRASG12V mutants. The compound was designed with strong binding affinity for KRAS and broad selectivity over HRAS and NRAS to achieve high levels of KRAS inhibition in human tumors. The Phase 1 KONQUER-101 trial (NCT06917079) is currently enrolling patients with KRASG12D, KRASG12V and KRASG12C solid tumors.
Strong Financial Position and Investor Support
The combined business expects to have approximately $490 million in cash, cash equivalents and marketable securities, consisting of BBOT's existing cash of approximately $130 million as of June 30, 2025, and net proceeds of approximately $365 million from the transaction after deducting approximately $15 million in offering expenses.
The PIPE investment attracted premier institutional investors including ADAR1 Capital Management, BC Capital, investment funds affiliated with Deerfield Management Company, Enavate Sciences, Eventide Asset Management, Novo Holdings A/S, Octagon Capital, Omega Funds, Paradigm BioCapital Advisors, StemPoint Capital LP, Surveyor Capital (a Citadel company) and Wellington Management.
Frank McCormick, PhD, Chairman of BBOT Board and David A. Wood Chair of Tumor Biology and Cancer Research at UC San Francisco, noted: "BBOT has made tremendous progress advancing its RAS-targeted therapeutics in the clinic. BBOT's drug candidates could provide significantly more patient benefit through optimizing target coverage and through exciting new combination therapies."
Leadership and Strategic Vision
Bihua Chen, Founder and CEO of Cormorant and CEO of Helix, emphasized the strategic importance of BBOT's approach: "BBOT's next generation KRAS ON inhibitors and its highly novel PI3K 'Breaker', which disrupts KRAS-driven PI3K activation, hold great promise to transform the treatment landscape for solid tumors driven by these oncogenes."
The company is led by Chief Executive Officer Eli Wallace, PhD; Chief Scientific Officer Pedro J. Beltran, PhD; Chief Medical and Development Officer Yong (Ben) Ben, MD, MBA; and Chief Financial Officer Uneek Mehra, MBA. The Board of Directors includes notable industry figures such as Frank McCormick, PhD, and representatives from leading investment firms including ARCH Ventures, Omega Funds, and Cormorant Asset Management.
